Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ABUS logo ABUS
Upturn stock ratingUpturn stock rating
ABUS logo

Arbutus Biopharma Corp (ABUS)

Upturn stock ratingUpturn stock rating
$3.24
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/14/2025: ABUS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $5.34

1 Year Target Price $5.34

Analysts Price Target For last 52 week
$5.34 Target price
52w Low $2.7
Current$3.24
52w High $4.72

Analysis of Past Performance

Type Stock
Historic Profit 13.98%
Avg. Invested days 40
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 607.14M USD
Price to earnings Ratio -
1Y Target Price 5.34
Price to earnings Ratio -
1Y Target Price 5.34
Volume (30-day avg) 4
Beta 1.24
52 Weeks Range 2.71 - 4.72
Updated Date 07/14/2025
52 Weeks Range 2.71 - 4.72
Updated Date 07/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.41

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -738.49%

Management Effectiveness

Return on Assets (TTM) -31.58%
Return on Equity (TTM) -79.02%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 495622998
Price to Sales(TTM) 94.82
Enterprise Value 495622998
Price to Sales(TTM) 94.82
Enterprise Value to Revenue 77.4
Enterprise Value to EBITDA -5.64
Shares Outstanding 191527008
Shares Floating 136355824
Shares Outstanding 191527008
Shares Floating 136355824
Percent Insiders 21.89
Percent Institutions 59.38

ai summary icon Upturn AI SWOT

Arbutus Biopharma Corp

stock logo

Company Overview

overview logo History and Background

Arbutus Biopharma Corp. (ABUS) was founded in 2007 (originally Tekmira Pharmaceuticals). It is a biopharmaceutical company focused on developing novel therapeutics for chronic hepatitis B virus (HBV) infection.

business area logo Core Business Areas

  • HBV Therapeutics: Development of therapies to cure chronic HBV infection, including RNAi therapeutics, capsid inhibitors, and other approaches.

leadership logo Leadership and Structure

William Collier is the President and CEO. The company has a typical organizational structure for a biopharmaceutical company, with research, development, clinical, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • AB-729 (RNAi Therapeutic): AB-729 is Arbutus's most advanced product candidate, an RNAi therapeutic designed to reduce hepatitis B surface antigen (HBsAg). It is currently in clinical development. There is no current market share but potential competitors include Assembly Biosciences, Arrowhead Pharmaceuticals, and Vir Biotechnology.
  • AB-101 (Capsid Inhibitor): AB-101 is an oral HBV capsid inhibitor, designed to disrupt HBV core protein assembly and viral replication. Currently in development. Competitors include Assembly Biosciences and other companies developing similar capsid inhibitors.

Market Dynamics

industry overview logo Industry Overview

The HBV therapeutics market is large and growing, driven by the high prevalence of chronic HBV infection worldwide. There is a significant unmet need for curative therapies.

Positioning

Arbutus is positioned as a key player in the HBV cure space, with a focus on developing novel RNAi and capsid inhibitor therapies. Competitive advantages include their intellectual property and clinical trial data.

Total Addressable Market (TAM)

The global hepatitis B therapeutics market is projected to reach billions of dollars. Arbutus is aiming to capture a significant share of this market by developing curative therapies.

Upturn SWOT Analysis

Strengths

  • Strong intellectual property portfolio
  • Experienced management team
  • Promising clinical trial data for AB-729
  • Focus on a significant unmet medical need

Weaknesses

  • Dependence on clinical trial success
  • High cash burn rate
  • Limited revenue generation
  • Subject to regulatory risks

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of HBV pipeline
  • Successful commercialization of AB-729
  • Acquisition or licensing of new technologies

Threats

  • Clinical trial failures
  • Competition from other HBV therapies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • VIR
  • GILD
  • JNJ

Competitive Landscape

Arbutus is among multiple companies seeking a cure for Hepatitis B, with each employing slightly different tactics. Arbutus has an advantage with their intellectual property and ongoing clinical trials, but is a much smaller company that the other competitors in the market.

Growth Trajectory and Initiatives

Historical Growth: Historically, growth has been based on R&D advancements, securing grants, and entering into collaboration agreements.

Future Projections: Future growth is dependent on the success of AB-729 and other pipeline products in clinical trials and eventual regulatory approval. Analyst projections vary based on perceived likelihood of success.

Recent Initiatives: Recent initiatives include advancing AB-729 into Phase 3 clinical trials, developing next-generation capsid inhibitors, and exploring new HBV targets.

Summary

Arbutus Biopharma is a development-stage biopharmaceutical company focused on curing HBV infection. The company's valuation hinges on the success of its pipeline, primarily AB-729. Clinical trial results will be a critical determinant of its success. Arbutus is dependent on external funding, partnerships and is susceptible to competition from larger, well established companies. It needs to show positive clinical outcomes and partnerships to survive.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Company Website
  • Analyst Reports
  • Market Research Reports

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are based on available data and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Arbutus Biopharma Corp

Exchange NASDAQ
Headquaters Warminster, PA, United States
IPO Launch date 2015-08-03
President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 44
Full time employees 44

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.